Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models
Open Access
- 3 October 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (19)
Abstract
Vessel co-option has been demonstrated to mediate colorectal cancer liver metastasis (CRCLM) resistance to antiangiogenic therapy. The current mechanisms underlying vessel co-option have mainly focused on “hijacker” tumor cells, whereas the function of the “hijackee” sinusoidal blood vessels has not been explored. Here, we found that the occurrence of vessel co-option in bevacizumab-resistant CRCLM xenografts was associated with increased expression of fibroblast activation protein α (FAPα) in the co-opted hepatic stellate cells (HSCs), which was dramatically attenuated in HSC-specific conditional Fap-knockout mice bearing CRCLM allografts. Mechanistically, bevacizumab treatment induced hypoxia to upregulate the expression of fibroblast growth factor–binding protein 1 (FGFBP1) in tumor cells. Gain- or loss-of-function experiments revealed that the bevacizumab-resistant tumor cell–derived FGFBP1 induced FAPα expression by enhancing the paracrine FGF2/FGFR1/ERK1/-2/EGR1 signaling pathway in HSCs. FAPα promoted CXCL5 secretion in HSCs, which activated CXCR2 to promote the epithelial-mesenchymal transition of tumor cells and the recruitment of myeloid-derived suppressor cells. These findings were further validated in tumor tissues derived from patients with CRCLM. Targeting FAPα+ HSCs effectively disrupted the co-opted sinusoidal blood vessels and overcame bevacizumab resistance. Our study highlights the role of FAPα+ HSCs in vessel co-option and provides an effective strategy to overcome the vessel co-option–mediated bevacizumab resistance.Keywords
Funding Information
- National Natural Science Foundation of China (81973340, 81803566, 81630095, 82003796, 81773758, 81973341)
- Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y036)
- Ministry of Science and Technology of China (2018ZX09711001-008-008)
- Natural Science Foundation, Research and Development Program of Guangdong Province (2020B1111110004, 2019A1515010144, 2019A1515011934, 2021A1515011233)
- National high-level personnel of special support program (2019)
- Science and Technology Program of Guangzhou (202002030010)
This publication has 70 references indexed in Scilit:
- IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liverJournal of Clinical Investigation, 2013
- Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in MiceGastroenterology, 2012
- Carbonic Anhydrase IX Promotes Tumor Growth and NecrosisIn Vivoand Inhibition Enhances Anti-VEGF TherapyClinical Cancer Research, 2012
- Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinomaMolecular Cancer, 2011
- Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionBlood, 2011
- FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cellsBMC Cancer, 2011
- Hepatic stellate cells: Partners in crime for liver metastases?Hepatology, 2011
- Delta-like 1 Serves as a New Target and Contributor to Liver Fibrosis Down-regulated by Mesenchymal Stem Cell TransplantationJournal of Biological Chemistry, 2011
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- rNAPc2 Inhibits Colorectal Cancer in Mice through Tissue FactorClinical Cancer Research, 2008